Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

The health condition can cause throat or oropharyngeal cancer in high-risk cases, though many of the symptoms which indicate ...

You may be reading this because you or someone you care about has nasal cavity or sinus cancer. Learning more can help you get ready to talk with your healthcare provider and understand the next steps ...

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory ...

Shilpa Biologicals and mAbTree Biologics secure US FDA orphan drug designation for breakthrough biologics to treat rare blood cancers: Our Bureau, Bengaluru Friday, March 13, 2026 ...

The White House explanation mostly checks out. Mostly.